StreetInsider.com News Articles

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 17:34:00 -0400

BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 7, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the six new non-executive employees received options to purchase 1,270,000 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 17:34:00 -0400

In the aggregate, the six new non-executive employees received options to purchase 1,270,000 shares of Annexon common stock. The options carry a ten-year

Annexon Biosciences (ANNX) PT Raised to $15 at JPMorgan

Wed, 30 Sep 2026 09:09:55 -0400

(Updated - September 30, 2026 9:09 AM EDT)

JPMorgan analyst Anupam Rama raised the price target on Annexon Biosciences (NASDAQ: ANNX) to $15.00 (from $14.00) while maintaining an Overweight rating.

The analyst commented, "Topline 15-month data from the Phase 3 ARCHER II study of vonaprument (C1q inhibitor) in geographic atrophy (GA) is expected in 4Q26. Recently, we hosted a group investor lunch with Annexon (ANNX) to discuss the upcoming readout and conducted a series of KOL calls. We wanted to pass on some key considerations for the update. At current levels, we see the 4Q ARCHER II readout of vonaprument in GA

Annexon Biosciences (ANNX) PT Raised to $15 at JPMorgan

Wed, 30 Sep 2026 09:09:55 -0400

(Updated - September 30, 2026 9:09 AM EDT)

JPMorgan analyst Anupam Rama raised the price target on Annexon Biosciences (NASDAQ: ANNX) to $15.00 (from $14.00) while maintaining an Overweight rating.

Form 4 Annexon, Inc. For: Sep 24 Filed by: Love Douglas

Fri, 25 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260925/27107558.html

Annexon presents Phase 3 GA trial data at retina conference

Thu, 24 Sep 2026 08:01:57 -0400

Annexon, Inc. (Nasdaq: ANNX) presented data from its Phase 3 ARCHER II clinical trial for vonaprument at The Retina Society 59th Annual Scientific Meeting in Los Angeles, California, running September 23-26, 2026.

Two oral presentations were delivered on September 25, 2026. The first, titled "Baseline Characteristics of Participants in the Phase 3 ARCHER II Trial in Dry AMD With GA," was presented by Ashkan Abbey, M.D., of Texas Retina Associates. The second, "Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial," was presented by Mark Barakat, M.D., of the

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Thu, 24 Sep 2026 08:00:00 -0400

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes

ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026

BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Thu, 24 Sep 2026 08:00:00 -0400

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes

ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 16:05:00 -0400

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 275,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 16:05:00 -0400

In the aggregate, the two new non-executive employees received options to purchase 275,500 shares of Annexon common stock. The options carry a ten-year

Annexon to Participate in Upcoming September Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA; and,
Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY;

Annexon to Participate in Upcoming September Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA; and,
Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY;

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Mon, 17 Aug 2026 16:05:00 -0400

In the aggregate, the three new non-executive employees received options to purchase 287,500 shares of Annexon common stock. The options carry a ten-year

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Thu, 13 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26920312.html

Form 144 Annexon, Inc. Filed by: WIGGANS THOMAS G

Thu, 13 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260813/26920312.html

Citizens Upgrades Annexon Biosciences (ANNX) to Market Perform

Thu, 13 Aug 2026 02:45:56 -0400

Citizens analyst Jonathan Wolleben upgraded Annexon Biosciences (NASDAQ: ANNX) from Market Underperform to Market Perform.

The analyst comments: “Adding vision preservation at month 24 as an independent, dual primary endpoint gives vonaprument a better opportunity to work in the Phase 3 ARCHER II trial; we are upgrading Annexon to Market Perform from Market Underperform based on our risk-adjusted, DCF-derived price target, and we view shares as fairly valued at these levels.

We continue to think vonaprument is unlikely to hit at the 15- month endpoint in 4Q26, but we think the downside on that miss is now more limited, with an opportunity

Citizens Upgrades Annexon Biosciences (ANNX) to Market Perform

Thu, 13 Aug 2026 02:45:56 -0400

Citizens analyst Jonathan Wolleben upgraded Annexon Biosciences (NASDAQ: ANNX) from Market Underperform to Market Perform.

We continue to think vonaprument is unlikely to hit at the 15- month endpoint in 4Q26, but we think the downside on that miss is now more limited, with an opportunity

Form 4 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26914610.html

Form 4 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26914610.html

Form 3 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26914606.html

Form 3 Annexon, Inc. For: Aug 10 Filed by: Blumenkranz Mark S.

Wed, 12 Aug 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26914606.html

Form 10-Q Annexon, Inc. For: Jun 30

Wed, 12 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260812/26912562.html